References
19
7. Azzarito V, Long K, Murphy NS, Wilson AJ (2013) Inhibition of [alpha]-helix-mediated
protein-protein interactions using designed molecules. Nat Chem 5:161–173
8. Smith MC, Gestwicki JE (2012) Features of protein-protein interactions that translate into
potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med 14:e16
9. Chakrabarti P, Janin J (2002) Dissecting protein-protein recognition sites. Proteins 47:334–
343
10. Miller S (1989) The structure of interfaces between subunits of dimeric and tetrameric proteins.
Protein Eng 3:77–83
11. Larsen TA, Olson AJ, Goodsell DS (1998) Morphology of protein–protein interfaces. Struct
6:421–427
12. Keskin O, Gursoy A, Ma B, Nussinov R (2008) Principles of protein − protein Interactions:
what are the preferred ways For proteins to interact? Chem Rev 108:1225–1244
13. Koch O, Cole J, Block P, Klebe G (2009) Secbase: database module to retrieve secondary
structure elements with ligand binding motifs. J Chem Inf Model 49:2388–2402
14. Bragg L, Kendrew JC, Perutz MF (1950) Polypeptide chain configurations in crystalline
proteins. Proceedings of the royal society of London. Ser A Math Phys Sci 203: 321–357
15. Tonlolo C, Benedetti E (1991) The polypeptide 310-helix. Trends Biochem Sci 16:350–353
16. Pauling L, Corey RB, Branson HR (1951) The structure of proteins: two hydrogen-bonded
helical configurations of the polypeptide chain. Proc Natl Acad Sci 37:205–211
17. Fodje MN, Al-Karadaghi S (2002) Occurrence, conformational features and amino acid
propensities for the π-helix. Protein Eng Des Sel 15:353–358
18. Barlow DJ, Thornton JM (1988) Helix geometry in proteins. J Mol Biol 201:601–619
19. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne
PE (2000) the protein data bank. Nucleic Acids Res 28:235–242
20. Bullock BN, Jochim AL, Arora PS (2011) Assessing helical protein interfaces for inhibitor
design. J Am Chem Soc 133:14220–14223
21. Edwards TA, Wilson AJ (2011) Helix-mediated protein–protein interactions as targets for
intervention using foldamers. Amino Acids 41:743–754
22. Liu X, Dai S, Zhu Y, Marrack P, Kappler JW (2003) The structure of a Bcl-xL/Bim fragment
complex: implications for Bim function. Immun 19:341–352
23. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DCS, Fairlie WD, Hinds
MG, Colman PM (2007) Structural insights into the degradation of Mcl-1 induced by BH3
domains. Proc Natl Acad Sci 104:6217–6222
24. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope
glycoprotein. Cell 89:263–273
25. Bruning JB, Parent AA, Gil G, Zhao M, Nowak J, Pace MC, Smith CL, Afonine PV, Adams
PD, Katzenellenbogen JA, Nettles KW (2010) Coupling of receptor conformation and ligand
orientation determine graded activity. Nat Chem Biol 6:837–843
26. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922) Pancreatic extracts in
the treatment of diabetes mellitus. Can Med Assoc J 12:141–146
27. White CJ, Yudin AK (2011) Contemporary strategies for peptide macrocyclization. Nat Chem
3:509–524
28. Kaspar AA, Reichert JM (2013) Future directions for peptide therapeutics development. Drug
Discov Today 18:807–817
29. Qvit N, Rubin SJS, Urban TJ, Mochly-Rosen D, Gross ER (2017) Peptidomimetic therapeutics: scientific approaches and opportunities. Drug Discov Today 22:454–462
30. Pelay-Gimeno M, Glas A, Koch O, Grossmann TN (2015) Structure-based design of inhibitors
of protein–protein interactions: mimicking peptide binding epitopes, Angewandte Chemie
(International Ed. in English), 54:8896–8927
31. Rezaei Araghi R, Keating AE (2016) Designing helical peptide inhibitors of protein-protein
interactions. Curr Opin Struct Biol 39:27–38
32. Henchey LK, Jochim AL, Arora PS (2008) Contemporary strategies for the stabilization of
peptides in the alpha-helical conformation. Curr Opin Chem Biol 12:692–697
19
7. Azzarito V, Long K, Murphy NS, Wilson AJ (2013) Inhibition of [alpha]-helix-mediated
protein-protein interactions using designed molecules. Nat Chem 5:161–173
8. Smith MC, Gestwicki JE (2012) Features of protein-protein interactions that translate into
potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med 14:e16
9. Chakrabarti P, Janin J (2002) Dissecting protein-protein recognition sites. Proteins 47:334–
343
10. Miller S (1989) The structure of interfaces between subunits of dimeric and tetrameric proteins.
Protein Eng 3:77–83
11. Larsen TA, Olson AJ, Goodsell DS (1998) Morphology of protein–protein interfaces. Struct
6:421–427
12. Keskin O, Gursoy A, Ma B, Nussinov R (2008) Principles of protein − protein Interactions:
what are the preferred ways For proteins to interact? Chem Rev 108:1225–1244
13. Koch O, Cole J, Block P, Klebe G (2009) Secbase: database module to retrieve secondary
structure elements with ligand binding motifs. J Chem Inf Model 49:2388–2402
14. Bragg L, Kendrew JC, Perutz MF (1950) Polypeptide chain configurations in crystalline
proteins. Proceedings of the royal society of London. Ser A Math Phys Sci 203: 321–357
15. Tonlolo C, Benedetti E (1991) The polypeptide 310-helix. Trends Biochem Sci 16:350–353
16. Pauling L, Corey RB, Branson HR (1951) The structure of proteins: two hydrogen-bonded
helical configurations of the polypeptide chain. Proc Natl Acad Sci 37:205–211
17. Fodje MN, Al-Karadaghi S (2002) Occurrence, conformational features and amino acid
propensities for the π-helix. Protein Eng Des Sel 15:353–358
18. Barlow DJ, Thornton JM (1988) Helix geometry in proteins. J Mol Biol 201:601–619
19. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne
PE (2000) the protein data bank. Nucleic Acids Res 28:235–242
20. Bullock BN, Jochim AL, Arora PS (2011) Assessing helical protein interfaces for inhibitor
design. J Am Chem Soc 133:14220–14223
21. Edwards TA, Wilson AJ (2011) Helix-mediated protein–protein interactions as targets for
intervention using foldamers. Amino Acids 41:743–754
22. Liu X, Dai S, Zhu Y, Marrack P, Kappler JW (2003) The structure of a Bcl-xL/Bim fragment
complex: implications for Bim function. Immun 19:341–352
23. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DCS, Fairlie WD, Hinds
MG, Colman PM (2007) Structural insights into the degradation of Mcl-1 induced by BH3
domains. Proc Natl Acad Sci 104:6217–6222
24. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope
glycoprotein. Cell 89:263–273
25. Bruning JB, Parent AA, Gil G, Zhao M, Nowak J, Pace MC, Smith CL, Afonine PV, Adams
PD, Katzenellenbogen JA, Nettles KW (2010) Coupling of receptor conformation and ligand
orientation determine graded activity. Nat Chem Biol 6:837–843
26. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922) Pancreatic extracts in
the treatment of diabetes mellitus. Can Med Assoc J 12:141–146
27. White CJ, Yudin AK (2011) Contemporary strategies for peptide macrocyclization. Nat Chem
3:509–524
28. Kaspar AA, Reichert JM (2013) Future directions for peptide therapeutics development. Drug
Discov Today 18:807–817
29. Qvit N, Rubin SJS, Urban TJ, Mochly-Rosen D, Gross ER (2017) Peptidomimetic therapeutics: scientific approaches and opportunities. Drug Discov Today 22:454–462
30. Pelay-Gimeno M, Glas A, Koch O, Grossmann TN (2015) Structure-based design of inhibitors
of protein–protein interactions: mimicking peptide binding epitopes, Angewandte Chemie
(International Ed. in English), 54:8896–8927
31. Rezaei Araghi R, Keating AE (2016) Designing helical peptide inhibitors of protein-protein
interactions. Curr Opin Struct Biol 39:27–38
32. Henchey LK, Jochim AL, Arora PS (2008) Contemporary strategies for the stabilization of
peptides in the alpha-helical conformation. Curr Opin Chem Biol 12:692–697